DECOY THERAPEUTICS INC (DCOY)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.12-1.75%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · DCOY
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -69.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
DCOY — private placement
Dated 2026-09-23
Entry into a Material Definitive Agreement. On September 22, 2026, Decoy Therapeutics Inc. (the “Company”) entered into a warrant inducement letter agreement (the “Inducement Letter”) with a holder (the “Holder”) of the Company’s outstanding Series A, Series B and Series C milestone-based common warrants issued on June 29, 2026 (the “Milestone Warrants”), pursuant to which the Holder agreed to exercise for cash, in full, the Series B Milestone Warrants (the “Existing Warrants”) to purchase an…
Why it matters: Decoy regained the required share price, but Nasdaq will monitor it for one year. A new breach could trigger a delisting letter.
Worry ifNasdaq says Decoy's bid price fell below the minimum during its review period. Nasdaq sends a delisting decision letter.
Less concerning ifDecoy stays in compliance through March 31, 2027, with no new bid-price notice from Nasdaq.
Why it matters: Written UK approval is a key step toward the planned trial. It also opens a possible $7 million warrant exercise.
Supportive ifDecoy reports written approval from the UK medicines agency to run the Phase 2a trial.
Worry ifDecoy reports that UK approval was denied or that the approval process has stalled.
Why it matters: Losses have stayed high, and Decoy has raised cash more than once. A smaller loss could ease pressure to raise more money.
Worry ifThe Nov. 13 report shows an operating loss above $2.63 million or continued negative cash flow.
Less concerning ifThe report shows a smaller operating loss than $2.63 million and less cash use than the prior quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$415 on $10,000 · ±4.2% | How much price usually moves either way. |
| Bad day | $1,238 loss on $10,000 · 12.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,386 loss on $10,000 · 93.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.